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Abstract
Background & Aims—Idiosyncratic drug-induced liver injury (DILI) is among the most
common causes of acute liver failure in the United States, accounting for approximately 13% of
cases. A prospective study was begun in 2003 to recruit patients with suspected DILI and create a
repository of biological samples for analysis. This report summarizes the causes, clinical features,
and outcomes from the first 300 patients enrolled.
Methods—Patients with suspected DILI were enrolled based on predefined criteria and followed
up for at least 6 months. Patients with acetaminophen liver injury were excluded.
Results—DILI was caused by a single prescription medication in 73% of the cases, by dietary
supplements in 9%, and by multiple agents in 18%. More than 100 different agents were
associated with DILI; antimicrobials (45.5%) and central nervous system agents (15%) were the
most common. Causality was considered to be definite in 32%, highly likely in 41%, probable in
14%, possible in 10%, and unlikely in 3%. Acute hepatitis C virus (HCV) infection was the final
diagnosis in 4 of 9 unlikely cases. Six months after enrollment, 14% of patients had persistent
laboratory abnormalities and 8% had died; the cause of death was liver related in 44%
Conclusions—DILI is caused by a wide array of medications, herbal supplements, and dietary
supplements. Antibiotics are the single largest class of agents that cause DILI. Acute HCV
infection should be excluded in patients with suspected DILI by HCV RNA testing. The overall 6-
month mortality was 8%, but the majority of deaths were not liver related.
Drug-induced liver injury (DILI) is a serious health problem that impacts patients,
physicians, the pharmaceutical industry, and government regulators.1–3 DILI is the most
common cause of death from acute liver failure and accounts for approximately 13% of
cases of acute liver failure in the United States.4 DILI is the most frequent adverse drug
event leading to abandonment of otherwise promising new drug candidates during
preclinical or clinical development, failure of drugs to achieve approval by the regulatory
agencies, and withdrawal or restriction of prescription drug use after initial approval.1–3
Idiosyncratic DILI from any single medication is a rare clinical event occurring in less than
1 per 10,000 to 100,000 of subjects who take the drug. The risk factors for this rare
occurrence and the pathogenesis are poorly understood.1–3,5,6 Most cases of DILI are
unpredictable and generally believed to be due to an immunoallergic reaction or an
abnormality in the metabolism of the agent and lack a dose relationship, although a dose
threshold has been suggested recently.5,7,8 The clinical presentation of DILI covers a wide
spectrum, from asymptomatic liver test abnormalities to symptomatic acute liver disease,
prolonged jaundice and disability, or overt acute or subacute liver failure. The recognition
and diagnosis of DILI are often difficult and delayed due to the need to exclude more
common competing causes of liver injury.
There is a growing awareness that nonprescription drugs, including herbal remedies and
other over-the-counter dietary supplements, are also important causes of DILI.9,10 For
example, organ toxicity associated with formulations that contain ephedra as a major
ingredient has led to their removal by regulatory authorities in some Western European
countries,11,12 and recent reports from the United States have emphasized the risks of use of
extracts of Chinese green tea (Camellia sinensis) that contain catechins as a major
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ingredient.13–15 Because numerous dietary supplements are consumed by large numbers of
US adults on a regular basis,16 the hepatotoxicity of dietary supplements may be
significantly underestimated.
It has been hypothesized that host genetic, immunologic, and environmental factors are
important in the pathogenesis of DILI.1–3,5,6,17 Thus, there is a growing expectation that use
of modern genome-wide association studies and other genetic analyses, coupled with careful
phenotyping of subjects, will improve the ability to identify subjects at high or low risk for
developing DILI from various drugs. This is an important part of the promise of
personalized medicine.18,19
The Drug-Induced Liver Injury Network (DILIN) was established in 2003 as a cooperative
agreement among the National Institutes of Health, 5 academic clinical centers, and a data
coordinating center.20 A major emphasis of DILIN has been to establish a protocol for the
identification and enrollment of patients with clinically significant DILI into a prospective
observational study and to create a registry and specimen repository of biological samples
that could be used for mechanistic studies on the etiology and prevention of DILI. The
design and development of the DILIN prospective study protocol21 and the process of
causality assessment22 have been presented elsewhere. In this report, we describe the
implicated agents, presenting clinical and laboratory features, and short-term outcomes of
the first 300 subjects enrolled in the ongoing DILIN prospective study.
Patients and Methods
The DILIN prospective study is an ongoing multicenter observational study. The study
design and procedures were approved by the institutional review board of each clinical
center site, and all enrolled patients provided written, fully informed consent. The study
design has been described in detail elsewhere.21 In brief, patients (2 years of age or older)
were enrolled in this study if there was a strong clinical suspicion that a liver injury event
was caused by a medication or an herbal agent occurring within 6 months before enrollment.
Additionally, patients must meet one of the following biochemical criteria for enrollment
into this study: (1) aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
level >5 times the upper limit of normal (ULN) or alkaline phosphatase level >2 times the
ULN (or pretreatment baseline if baseline level is abnormal) on 2 consecutive occasions, (2)
total serum bilirubin level >2.5 mg/dL along with elevated AST or ALT or alkaline
phosphatase level, or (3) international normalized ratio (INR) >1.5 with elevated AST or
ALT or alkaline phosphatase level. Known or suspected acetaminophen toxicity and a
history of bone marrow or liver transplantation before the liver injury event were exclusion
criteria. Patients with underlying hepatitis C virus (HCV), hepatitis B virus, or nonalcoholic
fatty liver disease were eligible if they developed superimposed DILI; however, those with
other types of underlying chronic liver disease (eg, autoimmune liver disease, sclerosing
cholangitis) were ineligible. Subjects with known or suspected acetaminophen
hepatotoxicity or a history of bone marrow or liver transplantation were excluded.
Eligible patients were seen for a baseline study visit, during which a medical history and a
detailed history of the liver injury event and exposure to the implicated agent(s) were
obtained and clinical, laboratory, histologic, and imaging results were extracted from the
medical chart. At this time, further laboratory testing was performed to more fully
characterize the DILI event and to exclude competing etiologies.1,2 All enrolled individuals
were followed up for at least 6 months, and those with evidence of chronic DILI were asked
to return at 12 and 24 months. Chronic DILI was defined as persistent liver-related
laboratory, radiologic, or histologic abnormalities at 6 months after DILI recognition.21
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In the clinical characterization of DILI, the ratio of serum ALT (as a multiple of its ULN) to
serum alkaline phosphatase (as a multiple of its ULN) has been designated as the R (for
ratio) value. Hepatocellular DILI is defined as R ≥ 5, cholestatic as R ≤ 2, and “mixed” as R
≥ 2 to R < 5.1,2 For the purpose of this report, “DILI recognition” was defined as the time
point when patients met the enrollment criteria. For brevity, herbal remedies, natural
products, vitamins, minerals, and other dietary supplements are referred to hereafter as
“dietary supplements.”
The diagnosis of DILI and the causal relationship between the liver injury event and the
implicated agent(s) were evaluated in a formal and standardized fashion by the DILIN
Causality Committee.22 The causality assessment was conducted for each case by using 2
different causality instruments: the widely used Roussel Uclaf Causality Assessment
Method (RUCAM)23–25 and assigning a DILIN causality score based on the consensus of at
least 3 hepatologist members of the committee.22 The RUCAM provides a semiquantitative
evaluation of causality by assigning −3 to +3 points to each of its 6 domains. Based on the
final score, a causal relationship between the implicated agent and the liver injury event was
categorized as highly probable (>8), probable (6 – 8), possible (3–5), unlikely (1 or 2), or
excluded (<0).23–25
The DILIN causality score categorizes the strength of causal association between the
implicated agent and the liver injury event as definite (>95% likelihood), highly likely
(75%–95%), probable (50%–74%), possible (25%–49%), and unlikely (<25%).21 In
addition, the severity of each DILI episode was categorized as one of 5 levels (mild,
moderate, moderate-hospitalized, severe, and fatal/transplant) as described elsewhere.21
Data Management and Statistical Analyses
Demographic and clinical data for the first 300 patients enrolled into this ongoing study
were extracted on December 1, 2007. Because causality adjudication lags behind data
collection, causality assessment was completed on only 254 of the 300 cases. No specific
sample size calculations were made to choose a sample size of 300 patients for this largely
descriptive report. Simple descriptive statistics, that is, mean ± SD, median with 25th and
75th percentiles, and frequency distributions, were used to characterize the cohort. Between-
group differences were assessed using the Kruskal–Wallis test for continuous variables and
the likelihood ratio test for categorical variables. For identifying predictors of DILI severity,
the severe and fatal/transplant categories were combined into 1 group (severe DILI) and
compared with the other 3 groups combined (mild/moderate DILI) using the likelihood ratio
test. Subsequently, multivariable logistic regression analysis, consisting of selected
clinically relevant variables (age, sex, race) and those with P <.1 on univariate analysis
(alcohol consumption, diabetes, duration between exposure and DILI recognition, and
pattern of liver injury), was conducted to identify factors independently associated with
advanced DILI. All statistical analyses were performed using SAS version 8.1 (SAS
Institute, Inc, Cary, NC). P <.05 was considered statistically significant.
Results
Presenting Features
The 300 patients included in this report were enrolled between September 2004 and
December 2007. Selected demographic and clinical characteristics are shown in Table 1.
Ninety-three percent were adults (≥18 years), 18% were older than 65 years, and 60% were
women. Six percent of patients had known liver disease before the onset of DILI, and 3%
had underlying human immunodeficiency virus infection. Sixty-nine percent had jaundice
during the DILI episode, and 60% were hospitalized. The median duration between first
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exposure to the implicated agent and DILI recognition was 42 (20–117) days. The duration
of exposure before DILI recognition was not different depending on gender or race. The
median duration between DILI recognition and study enrollment was 49.5 (21–104) days. At
the time of DILI recognition, the values for serum biochemistries (mean ± SD) were as
follows: ALT, 788 ± 967 U/L; alkaline phosphatase, 295 ± 272 U/L; total bilirubin, 6.3 ±
6.3 mg/dL; and INR, 1.5 ± 0.9.
Causative Agents
A single prescription medication was implicated in 217 (73%) of the 300 subjects, whereas
single or multiple dietary supplements were implicated in 28 patients (9%). In 55 patients
(18%), more than one prescription medicine or a combination of prescription medicine and
dietary supplement(s) was implicated. A complete list of agents implicated is provided in
Supplementary Table 1 (see supplemental material online at www.gastrojournal.org).
Among subjects in whom a single suspect prescription medication was implicated, the major
classes of agents were as follows: antimicrobials (antibacterial agents, antiviral agents,
antituberculosis agents, and so on) in 45.5%, central nervous system agents (antiepileptic
agents, antidepressants, antipsychotics) in 15%, immunomodulatory agents in 5.5%,
analgesics (nonsteroidal agents, muscle relaxants) in 5%, antineoplastic agents in 4%,
antihypertensive agents in 5%, and lipid-lowering agents in 3.4%. The most common single
implicated agents were amoxicillin/clavulanate (n = 23), nitrofurantoin (n = 13), isoniazid (n
= 13), and trimethoprim-sulfamethoxazole (n = 13).
Values of R: Types of DILI
The R value was calculated in 298 patients who had both serum ALT and alkaline
phosphatase values available on the day of DILI recognition. A total of 169 (57%) were
classified as hepatocellular, 68 (23%) as cholestatic, and 61 (20%) as mixed. The clinical
and laboratory features of patients with the 3 patterns of DILI are shown in Table 1.
Noteworthy were the younger age and higher proportion of women with hepatocellular
injury in comparison with cholestatic and mixed liver injury. The absence of preexisting
chronic liver disease in the mixed DILI is noteworthy but of unclear significance.
Causality Assessment
Causality adjudication has been completed in 254 of the 300 patients. Using expert opinion,
the likelihood of DILI as the reason for the liver injury was deemed definite in 32%, highly
likely in 41%, probable in 14%, and possible in 10%. In 9 individuals, DILI was deemed
unlikely to be responsible for the liver injury event; in these cases, the final diagnoses were
acute hepatitis C in 4, unknown in 3, and polymyositis and benign recurrent intrahepatic
cholestasis in 1 each (Supplementary Table 2; see supplemental material online at
www.gastrojournal.org).
The RUCAM scores assigned by the site investigator were available for 192 DILI cases
caused by a single prescription agent and were ranked as highly probable in 10%, probable
in 45%, possible in 36%, unlikely in 5%, and excluded in 4%. Because the RUCAM is
designed to attribute causality to an individual implicated agent rather than to assess the
global likelihood of DILI, cases with multiple possible causative agents have more than one
RUCAM score and those data are reported elsewhere.22
Course of Liver Injury
Following clinical presentation, the peak serum biochemistries (mean ± SD) were as
follows: ALT, 985 ± 1168 U/L; alkaline phosphatase, 390 ± 382 U/L; total bilirubin, 11.4 ±
10.2 mg/dL; and INR, 1.6 ± 1.4. The degree of severity of the liver disease was judged to be
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mild in 27%, moderate in 19%, moderate-hospitalized in 33%, severe in 15%, and resulting
in death or liver transplantation in 6%. Selected demographic and clinical characteristics of
patients with severe (severe and fatal/transplant cases combined) and mild/moderate (all
other cases) disease and the results of the univariate analyses are shown in Table 2. In the
multivariate logistic analysis including age, sex, race, coexistent diabetes mellitus, alcohol
consumption, smoking, biochemical pattern of liver injury, and the duration between first
exposure and DILI recognition as covariates, only the presence of diabetes and alcohol
consumption were independently associated with severe DILI (Supplementary Table 3; see
supplemental material online at www.gastrojournal.org). The presence of diabetes mellitus
was an independent risk factor for severe DILI (odds ratio, 2.69, 95% confidence interval,
1.14–6.45), whereas any alcohol use in the preceding 12 months was a negative predictor of
severe DILI (odds ratio, 0.33; 95% confidence interval, 0.15– 0.76). Interestingly, the
median duration between first exposure to the implicated agent and DILI recognition was
significantly longer in severe cases than in mild/ moderate cases (65.5 [33–263] vs 35.5 [19–
89] days; P = .006), but this association was not statistically significant in the multivariate
analysis (Table 2).
The median duration between DILI recognition and the peak value for ALT was 1 (0–7)
days, for alkaline phosphatase was 4 (0–16) days, and for total bilirubin was 7 (0–17) days.
There was no statistically significant relationship between any of these durations and age,
pattern of liver injury, implicated agent categories (single prescription agent vs dietary
supplement[s] vs multiple agents), and causality or severity scores.
At the 6-month follow-up visit, 13.6% of enrolled patients had met predefined criteria for
chronic DILI, 8% had died, and 2.1% had undergone liver transplantation.21 Features of the
implicated agent, patient age, and pattern of DILI were not associated with chronicity,
mortality, or need for transplantation (Table 3). Among DILI subjects with jaundice at or
after presentation (total serum bilirubin level ≥2.5 mg/dL), the median duration between
peak bilirubin level and 50% reduction in total bilirubin level was 13 days (4–30 days) and
the median duration from peak bilirubin level to a level <2.5 mg/dL was 26.5 days (3–54
days) (Table 4). The patterns and times of changes in serum bilirubin levels did not correlate
with clinical features of the DILI cases.
Table 5 shows selected characteristics and causes of death in the 27 patients with suspected
DILI who died or received liver transplantation within 180 days following the DILI event.
Interestingly, among the 18 patients who died, the cause of death was judged by the
investigators to be liver related in only 8 (44%). The mortality in patients with
hepatocellular DILI with peak serum total bilirubin level ≥2.5 mg/dL was significantly
higher than in those with hepatocellular DILI with serum total bilirubin level <2.5 mg/dL
(13.4% vs 2.4%, respectively; P = .04). However, the mortality rate in patients with
cholestatic DILI with serum total bilirubin level ≥2.5 mg/dL was not statistically different
than in those with cholestatic DILI with bilirubin level <2.5 mg/dL (15% vs 10%,
respectively; P = .66). Among 17 patients who died from liver failure or received a
transplant, 14 had hepatocellular DILI, whereas 2 had mixed and 1 had cholestatic DILI
(Table 5).
Dietary Supplements
Dietary supplements were implicated in 33 subjects with DILI; one or more dietary
supplements were implicated in 28, whereas they were implicated in combination with one
or more prescription agents in the remaining 5. In many cases, multiple agents were being
used; even when a single preparation was used, it often contained multiple herbal or
nutritional components, so that attribution of liver injury to a single component was rarely
possible. The names of all implicated herbal agent(s) are shown in Supplementary Table 1
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(see supplemental material online at www.gastrojournal.org). The stated reasons for
consuming these dietary supplements were muscle building (n = 11), weight loss (n = 8),
insomnia (n = 2), general well-being (n = 2), preventing common cold (n = 2), increasing
energy levels (n = 2), and hot flashes (n = 1). Compared with 217 cases due to single
prescription medications, 28 DILI cases caused by dietary supplements showed few
differences, none of which were statistically significant (Supplementary Table 4; see
supplemental material online at www.gastrojournal.org). Patients with DILI due to dietary
supplements had higher mean levels of serum total bilirubin (14.7 ± 13 vs 10.6 ± 9.9 mg/dL;
P = .11) and longer median duration for the jaundice to resolve (68 vs 35 days; P = .08), but
these trends were of borderline statistical significance. There were no instances of Stevens–
Johnson syndrome or death due to dietary supplements, but one subject with suspected DILI
due to CVS Spectravite developed acute liver failure necessitating liver transplantation.
Discussion
This is an initial analysis of an ongoing prospective study of DILI being performed in the
United States, the primary aim of which is to develop well-characterized cases of
medication-related liver injury on which to conduct hypothesis-driven research aimed at
developing means to diagnose, prevent, and treat DILI. Among the first 300 cases identified,
more than 100 different medications, herbal supplements, and dietary supplements were
implicated. Newly identified hepatotoxic drugs that had received Food and Drug
Administration warnings between 2003 and 2007 were identified by DILIN (eg,
telithromycin, leflunomide, duloxetine), suggesting that a prospective network such as
DILIN may be able to provide early detection of the hepatotoxic potential of newly released
medications. An important finding was that more than one agent was implicated in causing
liver injury in ~20% of cases, a frequency significantly higher than the 9% reported from a
similar study that had been conducted in Spain.26 The reason for this difference is unclear,
but it may reflect higher use of medicines by the US population. Consistent with previous
reports, antimicrobials represented the single largest class of agents to have caused
DILI.26–29 It remains unclear why antimicrobials have such a high propensity to cause DILI,
but it may be related to greater use of antimicrobials in the general population or biological
reasons such as underlying infection and inflammation conferring increased susceptibility.30
The proportion of cases with suspected DILI caused by dietary supplements was nearly 10%
and is higher than reported in the Spanish registry, likely reflecting a greater use of these
products by the US population.26 None of the subjects with suspected DILI caused by
dietary supplements were children. The intake of these compounds may be infrequent in
children; however, we cannot exclude the possibility that children may be less susceptible
than adults to hepatotoxicity by dietary supplements. Compounds that claim to promote
muscle building and weight loss were the 2 most common classes of dietary supplements,
accounting for nearly 60% of cases. The total number of cases of DILI due to dietary and
herbal supplements was small (n = 28), and no single supplement was responsible for more
than one case, although, as a class, supplements that include extracts of green tea as a major
ingredient caused at least 6 of the 28 cases.
The findings regarding the rate of change of serum total bilirubin levels after onset of DILI
may be of practical relevance in monitoring and counseling patients with DILI (Tables 3 and
4). The total serum bilirubin level reached its peak an average of 1 week after DILI
recognition, and this timing was independent of patient age, pattern of liver injury, or
whether caused by prescription agents or dietary supplements. Among patients with
jaundice, it took nearly 1 month on average for the jaundice to resolve, but this interval was
longer in the elderly, in patients with cholestatic forms of DILI, or in patients with DILI
caused by dietary supplements.
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Acute hepatitis C was the final diagnosis in 4 of the 9 cases that were adjudicated as
“unlikely” to be DILI. Anti-HCV was initially negative in 2 subjects, but they subsequently
seroconverted to detectable viremia. In 2 other patients, initial testing revealed the presence
of anti-HCV, but the site investigators at the time of enrollment believed them to represent
chronic rather than acute hepatitis C, largely because both patients lacked recent risk factors
for acquiring viral hepatitis. However, the availability of additional clinical data (eg, liver
histology) made HCV infection rather than DILI the likely explanation for the acute event
(Supplementary Table 2). These 4 patients did not admit to high-risk behaviors (eg, recent
drug abuse), but 3 had been hospitalized recently. These findings suggest that, even in the
absence of risk factors, acute hepatitis C should be excluded by testing for serum HCV RNA
in all patients with suspected DILI, especially if there is a history of recent hospitalization
and a hepatocellular pattern of injury. In fact, in light of these findings, our protocol was
amended to obtain HCV RNA at the baseline visit in all enrolled patients. As better
diagnostic tests become available for specific causes of acute liver injury, more cases of
suspected DILI may be found to have other etiologies. Indeed, in a recent series from the
United Kingdom, retrospective testing for antibody to hepatitis E virus in 69 patients with
presumed DILI identified 6 patients with probably acute hepatitis E.31
In a cohort study of 461 patients with DILI from Spain, female sex, hepatocellular patterns
of liver injury, and total serum bilirubin level on presentation were identified as independent
predictors of acute liver failure.26 In the current US study, there was no relationship between
female sex and severity of DILI; furthermore, the positive association between
hepatocellular injury and severity of DILI was of borderline significance. Total serum
bilirubin levels were higher in patients with severe DILI, but bilirubin is used in the criteria
to define severity and therefore was not used in the multivariate analysis of factors
correlating with severity and outcome. In this study, the presence of diabetes mellitus was
found to be an independent risk factor for severe DILI. Diabetes was not considered as a
covariate in previous studies from Spain26 and Sweden.29 However, epidemiologic and
animal studies suggest that diabetes is associated with an increased incidence of acute liver
failure and severity of DILI.32–35 Alcoholism is generally believed to be a risk factor for
developing DILI (particularly injury due to acetaminophen), and, in the RUCAM causality
instrument, points are given in favor of DILI for alcohol intake. However, outside of
acetaminophen and isoniazid toxicity, the association between alcohol consumption and
susceptibility to DILI has not been evaluated rigorously.1–3 The finding that alcohol
consumption protected against severe DILI in this study was surprising and of uncertain
significance. A major difficulty is the variability of definitions of alcohol intake and
alcoholism in various studies and causality instruments. In this study, alcohol consumption
was defined as any alcohol intake in the preceding 12 months. Additional studies are needed
to determine if alcohol consumption may play a role in DILI susceptibility by comparing
subjects with DILI with suitably matched controls without DILI. Previous studies also have
shown associations between severe DILI and older age329 and eosinophil counts,35 but these
were not confirmed in this study. The latter may not have been identified due to the lag
between DILI recognition and study enrollment (median ~42 days). In a study of 95 patients
with suspected DILI from Japan,36 the duration of exposure to the implicated agent was
longer in cases of acute liver failure compared with less severe cases (81 ± 89 vs 30 ± 44
days, respectively; P <.0001 by univariate analysis). In this study, the duration of exposure
to the implicated agent was significantly longer in individuals with severe DILI, but this
relationship was not statistically significant on multivariate analysis.
The mortality rate of DILI is generally high, particularly in cases with jaundice and a
hepatocellular pattern of injury, colloquially known as “Hy’s rule.”37 The 8% mortality rate
in this study is in general agreement with prior reports.26,29 Although patients with
cholestatic DILI have been thought to have a better prognosis than those with hepatocellular
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DILI,37 this association was not found in this study and has not been consistently found in
recent large case series from Europe26,29 (Table 6). Importantly, most of the fatalities in
patients with cholestatic forms of DILI were due to reasons other than liver failure (Table 5).
The mortality rate of hepatocellular forms of liver injury with jaundice in this study was
15%, which is compatible with Hy’s rule, which states that the average mortality rate in
patients with jaundice and a hepatocellular pattern of injury from DILI is at least 10%.38
Limitations of our study include the potential for selection bias, the arbitrary laboratory
entry criteria, and the lack of international standards for diagnosing DILI. However, all
patients were prospectively studied and had undergone a complete serologic, radiologic, and
clinical assessment by experienced hepatologists. In addition, causality was determined by a
committee of experts using standardized terminology.21 Overall, we may have enrolled
patients with more severe DILI than is encountered in the general population and in other
prior studies.39 This may be due to the fact that hospitalized patients were more likely to be
referred to a DILIN investigator or undergo a complete evaluation. In addition, nearly 50%
of our patients had undergone liver biopsy. However, a reasonable number of pediatric
patients were enrolled (7%) and a broad distribution of race/ethnicities was enrolled. In
addition, our limited sample size precludes robust analysis of risk factors for DILI outcome.
We plan to conduct additional multivariate analyses once the total enrollment increases.
Finally, susceptibility risk factors for DILI will require comparing enrolled patients with
control patients who took the same medication but did not develop liver injury. Appropriate
controls will be recruited as the number of DILI cases caused by individual medications
increases in number.
In summary, DILI in the United States is caused by a wide variety of prescription and
nonprescription medications, nutritional supplements, and herbal supplements. The
antimicrobials represent the single largest class of agents that cause DILI, accounting for at
least 45% of cases. At least 20% of patients with DILI ingest more than one potentially
hepatotoxic agent. Acute hepatitis C should be carefully excluded before attributing a case
of acute liver injury to DILI. In this study, coexistent diabetes mellitus was an independent
risk factor for more severe DILI, while alcohol consumption was a negative predictive
factor. DILI with jaundice from hepatocellular liver injury carries a high mortality rate, but
the mortality rate associated with cholestatic forms of DILI is also appreciable although
often caused by worsening of the underlying condition or an unrelated disease. DILI still
represents an important and problematic cause of acute liver disease in the United States,
and further efforts are needed in defining its pathogenesis and developing means for its early
detection, accurate diagnosis, prevention, and treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2




(n = 51) P
Age, mean ± SD (y) 50 ± 18 46 ± 16.3 .15
Proportion aged ≥65 years (%) 23 11 .06
Female (%) 57 59 .80
Self-reported race (%)
  White 81 67 .10
  Black 11 18
  Asian 2 8
Body mass index, mean ± SD (kg/m2) 26.4 ± 5.9 27.2 ± 7.8 .90
Alcohol use (%) 57 32 .001
Preexisting liver disease (%) 6 9 .50
Diabetes (%) 25 37 .07
Days between exposure and DILI recognition, median (25th, 75th percentiles) 35.5 (19, 89) 65.5 (33, 263) .006
Implicated agent(s) (%)
  Single prescription agent 74 80 .40
  Single or multiple dietary supplements 7.2 2
  Multiple prescription or prescription plus dietary supplements 19 18
Liver biochemistries, values at DILI onset (mean ± SD)
  ALT (U/L) 610 ± 685 1218 ± 1559 <.001
  Alkaline phosphatase (U/L) 309 ± 284 283 ± 247 .60
  Bilirubin (mg/dL) 5.2 ± 5.1 9.1 ± 8.4 <.001
  INR 1.2 ± 0.3 2.3 ± 1.6 <.001
Liver biochemistries, peak values (mean ± SD)
  ALT (U/L) 733 ± 726 1513 ± 1734 <.001
  Alkaline phosphatase (U/L) 388 ± 399 401 ± 354 .001
  Bilirubin (mg/dL) 8.9 ± 9.4 18.4 ± 10.2 .50
  INR 1.2 ± 0.3 2.9 ± 2.5 <.001
Absolute eosinophil count/µL (mean ± SD) 195 ± 344 197 ± 293 .70
Pattern of liver injury (%)
  Hepatocellular 50 69 .06
  Cholestatic 27 19
  Mixed 23 12.5
Causality score
  Definite 32 25.5 .17
  Highly likely 41.5 35
  Probable 13 22
  Possible 10 10
  Unlikely 2.6 8
Chronic DILI (%) 17 12 1.0
Liver-related mortality (%) 0 23 <.001

















(n = 51) P
Liver transplantation (%) 0 2.9 .17
Mild DILI: elevated ALT and/or alkaline phosphatase level but serum total bilirubin level <2.5 mg/dL and INR <1.5; moderate DILI: elevated
ALT and/or alkaline phosphatase levels and serum total bilirubin ≥2.5 mg/dL or INR ≥1.5; moderate-severe DILI: elevated ALT, alkaline
phosphatase, bilirubin, and/or INR levels and patient is hospitalized for DILI or if ongoing hospitalization is prolonged; severe DILI: elevated ALT
and/or alkaline phosphatase level and serum bilirubin level ≥2.5 mg/dL and hepatic failure (INR ≥1.5, ascites or encephalopathy); fatal/ transplant:
patient dies or undergoes transplantation because of DILI event. Advanced DILI consisted of severe and fatal/transplant cases, whereas
nonadvanced DILI consisted of 3 other categories.
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Table 6








Björnsson and Olsson29 12.7 7.8 2.4
Andrade et al26 7 5 2
Chalasani et al (current report) 7.5 14.3 2.1
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